SAN DIEGO, July 30, 2026
Aspen Neuroscience, Inc. has received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA) for sasineprocel (ANPD001), its investigational autologous induced pluripotent stem cell-derived therapy being developed for Parkinson’s disease (PD). The designation represents an important regulatory milestone for Aspen’s regenerative medicine program and is based on results from the ongoing Phase 1/2a ASPIRO clinical trial, which the company said have demonstrated encouraging early clinical activity and a favorable safety profile. Sasineprocel previously received FDA Fast Track designation, and the addition of RMAT status provides Aspen with opportunities for increased FDA interaction and expedited development support as the company seeks to advance a potentially disease-modifying treatment for Parkinson’s disease.
RMAT Designation Strengthens Regulatory Path for Sasineprocel
The FDA RMAT designation was established under the 21st Century Cures Act to accelerate the development and review of regenerative medicine therapies intended to treat, modify, reverse or cure serious conditions. Eligible programs must demonstrate preliminary clinical evidence indicating the potential to address an unmet medical need. For Aspen, RMAT designation may enable early and frequent interactions with the FDA regarding clinical development requirements and may provide potential eligibility for Priority Review and Accelerated Approval pathways. The designation adds to the previous Fast Track status for sasineprocel and highlights the regulatory momentum surrounding Aspen’s personalized regenerative medicine program. Parkinson’s disease represents a substantial unmet medical need, and Aspen is developing sasineprocel with the goal of addressing the underlying neuronal loss associated with disease progression rather than focusing exclusively on management of symptoms.
ASPIRO Trial Evaluates Autologous Dopaminergic Cell Therapy
The ongoing Phase 1/2a ASPIRO trial is an open-label, multicohort and multicenter clinical study evaluating the safety, tolerability and activity of surgically delivered autologous dopaminergic neuron precursor cells (DANPCs) in people with Parkinson’s disease. The cells are delivered directly into the putamen, a brain region where restoration of dopamine signaling is needed. According to Aspen, early findings from ASPIRO supported the RMAT designation by demonstrating encouraging preliminary clinical activity and a favorable safety profile. Sasineprocel is designed as a single-dose, personalized cell therapy created from each individual patient’s own cells. The manufacturing process begins with a small skin punch biopsy, after which the collected cells are reprogrammed into induced pluripotent stem cells (iPSCs) and subsequently differentiated into dopaminergic neuron precursor cells. The resulting cellular product is then administered to the putamen using image-guided delivery.
Advertisement
Cell Replacement Strategy Targets Parkinson’s Disease Progression
Aspen’s therapeutic strategy is designed to replace dopaminergic neurons lost during Parkinson’s disease progression and potentially reconstruct damaged neural circuitry. Following transplantation, the DANPCs are intended to establish a biologically active cellular environment supporting engraftment, survival and functional integration. The company believes this approach could ultimately help restore neuronal function, potentially improve motor function and quality of life, and provide durable clinical benefit. A key feature of sasineprocel is its autologous design, meaning the therapeutic cells originate from the individual patient rather than from a donor. According to Aspen, this approach eliminates the need for the immunosuppression generally required with donor-derived allogeneic cell therapies. The company describes sasineprocel as the most advanced autologous investigational cell therapy in the United States for Parkinson’s disease. With both RMAT and Fast Track designations, Aspen now has access to regulatory mechanisms intended to support more efficient development of therapies addressing serious conditions with unmet medical needs. Continued evaluation through the ASPIRO program will be important in determining the therapy’s safety, clinical activity and potential to deliver durable benefits for patients. The regulatory milestone also highlights growing momentum behind iPSC-derived regenerative medicine and personalized cell therapies for neurodegenerative diseases, as developers seek approaches capable of repairing or replacing neuronal function rather than solely managing symptoms.
Source: Aspen Neuroscience press release
